Early ADHD Treatment with Stimulants May Reduce Severe Mental Illness Risk in Adulthood

A large-scale study has found that early treatment of ADHD with stimulant medications may lower the risk of severe mental illness in adulthood. Researchers analysed health records from nearly 700,000 individuals in Finland, uncovering a potential long-term benefit of childhood intervention. The findings, published in JAMA Psychiatry, could reassure families and clinicians about the safety of ADHD drugs like methylphenidate. The study was led by teams at University College Dublin and the University of Edinburgh. They tracked ADHD patients over time, focusing on those who received stimulant treatment before age 13. Results showed a reduced likelihood of developing psychotic disorders, such as schizophrenia, later in life.

Advanced statistical methods were used to adjust for regional differences in prescribing habits. The research found no evidence that methylphenidate increased the risk of psychosis. Instead, early intervention appeared to provide lasting protection. Dr. Colm Healy, the lead author, highlighted the need for age-specific studies as adult ADHD diagnoses rise. Professor Ian Kelleher added that the findings should ease concerns about long-term medication safety. The study aligns with a 2024 German report confirming methylphenidate's safety in children and adolescents, reflecting a growing consensus on its benefits. Researchers stressed the importance of early diagnosis, thorough assessment, and evidence-based treatment. They urged clinicians to consider these findings when managing ADHD in young patients.

The study suggests that treating ADHD with stimulants in childhood may prevent serious mental health issues later. Published in a leading medical journal, the results provide clearer guidance for doctors and families. Early and well-managed treatment remains a key factor in improving long-term outcomes for those with ADHD.